—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Genmab AS (GMAB) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GMAB, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 56/100 · S&P 500 fund at 66, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-13
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 93th percentile of the window, +3.6% over 20 sessions. Factor regime → 2026-10-13
  • Sector × region Health care in US: +1.5% week · +1.5% month · +7.6% quarter · +19.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-13
  • Sovereign pressure Index -0.13 · down 0.58 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-13
How it trades on rate days beta 0.60 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How GMAB has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.60 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Genmab AS moved 0.60% on average · correlation 0.16 · higher than 55% of US names
  • Beta, last 3 months 0.48 about the same as over the year
  • On the 10 worst bond days −1.13% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.23% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against GMAB on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Genmab AS

GMAB in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development.
Where it sits in the stack
Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line.
Who it is priced against
Closelooknet's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.
Why Closelooknet tracks it
It carries a Closelooknet score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.
What the diary watches
Whether new approvals or expanded partner deals convert its pipeline into steadier royalty income, since much of its revenue still depends on collaborations with other drugmakers.

Genmab AS (GMAB) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 51/100 composite (momentum 84, quality 72, valuation 34) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months · buybacks 430 m USD in FY2025

Dividends and capital return

What GMAB pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 430 m USD 1.9% of today's market value
  • Share count −3.0% in FY2025 128 m USD of stock-based compensation in the year
  • Capital returned 430 m USD · 37% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-14

Quick answers

What is Genmab AS (GMAB)?

Genmab AS trades as GMAB on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-14.

Is GMAB in a Closelooknet index?

Not currently — Genmab AS is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-14.

What is Genmab AS's Closelooknet composite score?

51 out of 100, with momentum 84, quality 72 and valuation 34 sub-scores, as of 2026-10-14. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does GMAB trade against its moving averages?

Uptrend stack intact: Trades +8.1% vs the 50-day and +22.8% vs the 200-day average, 9% below the 52-week high and +54.8% off the 52-week low; a golden cross printed 34 sessions ago. Computed from daily closes. As of 2026-10-13 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Genmab AS compare with its peers?

Against its peer group (Biotechnology · US), Genmab AS (GMAB) sits 9.0% below its 52-week high, 8.1% above its 50-day average; Halozyme Therapeutics Inc (HALO) is 6.2% below, BeiGene, Ltd. (ONC) is 9.4% below, argenx NV ADR (ARGX) is 25.2% below. Put any of them next to GMAB in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Genmab AS trade when bond yields rise?

Over the past year Genmab AS had a beta of 0.60 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 55% of US names. On the 10 sessions in which long bonds fell most it moved −1.13% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Genmab AS do?

Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development. Closelooknet's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.

Where does Genmab AS sit in the AI build-out?

Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line. It carries a Closelooknet score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.

Does Genmab AS pay a dividend?

No cash distribution shows in Genmab AS’s price series over the last three years. In fiscal 2025 the company bought back 430 m USD of its own shares, 37% of that year’s free cash flow. The share count fell 3.0% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for GMAB, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.